Table 3

Additional Sensitisations (England & Wales) for Different Test Sensitivities

Additional Sensitisations/Year 1

Incremental Cost-Effectiveness Ratio 2


RhD NIPD sensitivity 3

Scenario 1 4

Scenario 2 5

Scenario 1 (£/sensitisation)

Scenario 2 (£/sensitisation)


94.8% 6

54

744

3,005 (235)

883 (682)


96.0%

42

573

3,863 (302)

1,146 (885)


97.0%

31

430

5,234 (409)

1,527 (1,179)


98.0%

21

283

7,727 (604)

2,320 (1,793)


98.4%

17

226

9,545 (747)

2,906 (2,244)


99.0%

10

141

16,226 (1,269)

4,658 (3,597)


99.2%

8

113

20,282 (1,586)

5,812 (4,488)


99.4%

6

85

27,043 (2,115)

7,726 (5,966)


99.7%

3

42

54,086 (4,231)

15,636 (12,075)


99.9%

1

14

162,258 (12,692)

46,908 (36,225)


1 Assuming current serology is 100% accurate.

2 Incremental cost i.e. £ sterling saved per additional sensitisation produced. Figures in brackets ( ), assumes royalty fee negotiated at £2.00 per test.

3 Sensitivity range based on values reported in literature [13,16]

4 Antenatal anti-D prophylaxis directed by RhD NIPD results & postnatal anti-D by serology (1.3% risk) [2]

5 Postnatal anti-D prophylaxis based on RhD NIPD antenatal result (13.2% risk) [3]

6 Meta-analysis figure for diagnostic accuracy [13]

Szczepura et al. BMC Pregnancy and Childbirth 2011 11:5   doi:10.1186/1471-2393-11-5

Open Data